Humoral and cellular immunogenicity and safety following a booster dose of a tetravalent dengue vaccine 5+ years after completion of the primary series in Singapore: 2-year follow-up of a randomized phase II, placebo-controlled trial

• Main Authors: Juliana Park (Author), Sophia Archuleta (Author), May-Lin Helen Oh (Author), Lynette Pei-Chi Shek (Author), Hao Wang (Author), Matthew Bonaparte (Author), Carina Frago (Author), Alain Bouckenooghe (Author), Frederique Jantet-Blaudez (Author), Sarah Begue (Author), Sophie Gimenez-Fourage (Author), Anke Pagnon (Author)
• Format: Book
• Published: Taylor & Francis Group, 2021-07-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

The tetravalent dengue vaccine (CYD-TDV) is approved for use as a 3-dose series for the prevention of dengue in seropositive individuals ≥9 years. A randomized, placebo-controlled, phase II study of a booster dose of CYD-TDV in individuals who completed the 3-dose schedule >5 years previously (NC...